NEW YORK (GenomeWeb) – Israeli epigenetics-based diagnostics firm Nucleix announced on Monday that it has raised more than $5 million in private financing.

The company's lead product is the urine-based Bladder EpiCheck for detecting bladder cancer. The funding will go toward clinical trials for the test, as well as efforts to gain European CE marking and US Food and Drug Administration regulatory approval, Tel Aviv, Israel-based Nucleix said. Funds will also be used to develop diagnostic tests for other cancers.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

A new analysis examines the gender gap among paper authors in the sciences and says it may take decades or more to close.

Researchers have uncovered signals of selection that may enable the Bajau people to free five hundreds of feet deep, Reuters reports.

In Science this week: paternally inherited cis-regulatory structural variants in autism, and more.

A new report outlines issues facing the implementation of personalized medicine in the UK, the Independent reports.

May
15
Sponsored by
Tecan

This webinar will discuss how an algorithm-driven synthetic biology system can enable engineering of biological systems for a range of applications.

Jun
20
Sponsored by
PerkinElmer

In this webinar, Michael Quail of the R&D Sequencing team at the Wellcome Trust Sanger Institute will provide an expert perspective on library prep for next-generation sequencing.

Jun
28
Sponsored by
PerkinElmer

This webinar will review a standardized, high-throughput, and fully automated library prep protocol for human metagenomic analysis.